Research Analyst at Leerink
Kushal Patel is a Senior Associate specializing in biopharma sector strategy, research, and mergers & acquisitions at SVB Securities in New York. He has covered companies in the biotechnology and pharmaceutical industries, leveraging his strong clinical and financial background, although specific firm names and performance metrics are not publicly listed. Patel began his career at Guggenheim Partners and transitioned into investment banking after earning his PharmD, reflecting a unique blend of healthcare and finance expertise. He is professionally active on LinkedIn and holds advanced healthcare and financial credentials, but information on securities licenses or FINRA registration is not available.
Kushal Patel sought clarification on the daily and weekly oral maintenance doses (17.5 mg, 27.5 mg daily; 110 mg weekly) and whether there would be up-titration from subcutaneous to oral doses.
Brian Lian (President and CEO, Viking Therapeutics) confirmed the oral doses and clarified that no up-titration is anticipated when transitioning from subcutaneous to oral due to the significantly higher subcutaneous exposures.
Kushal Patel sought clarification on the specific daily and weekly oral maintenance doses (17.5 mg, 27.5 mg daily; 110 mg weekly) and whether there would be up-titration when transitioning from subcutaneous to oral 27.5 mg.
Brian Lian (President and CEO, Viking Therapeutics) confirmed the oral doses and clarified that no up-titration is expected when transitioning from subcutaneous to oral due to significantly higher subcutaneous exposures.
Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.
Trusted by leading investment firms and analysts